A DOT1L-specific methyltransferase inhibitor, EPZ004777, was shown to extend survival in a mixed lineage leukemia (MLL)-rearranged leukemia mouse model and attenuated global H3K79 methylation in human leukemia cell lines [1]. Here, KMT2A is linked to leukemia.